Restenex
Latest Information Update: 31 Oct 1996
Price :
$50 *
At a glance
- Originator Cortex Pharmaceuticals
- Class
- Mechanism of Action Calpain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular restenosis
Most Recent Events
- 31 Oct 1996 Discontinued-Preclinical for Vascular restenosis in USA (Unknown route)
- 03 Jan 1996 New profile
- 03 Jan 1996 Preclinical development for Vascular restenosis in USA (Unknown route)